Experimental models in Alzheimer's disease;Modelos experimentales de la enfermedad de Alzheimer

Neurologia

Volumn 24, Issue 4, 2009, Pages 255-262

  Manzano, Sagrario ^a,b   Gonzalez J L ^b   Marcos, A ^b   Payno, M ^c   Villanueva, C ^c   Matias Guiu J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Unidad de Estudio de la Cognición Y la Conducta

^c Sección de Neuropsicología   (Spain)

Author keywords

Alzheimer's disease; Cellular models; Experimental models; Transgenic mice; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOENZYME; ENZYME; MEMBRANE METALLOENDOPEPTIDASE; OLIGOMER; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN DAMAGE; CELL CULTURE; CETACEA; CHICK EMBRYO; DATA BASE; ENZYME DEGRADATION; EXPERIMENTAL MODEL; HIPPOCAMPUS; MEDLINE; MUTANT; NERVE CELL; NONHUMAN; PRIMATE; PROTEIN EXPRESSION; PROTEIN METABOLISM; PUBLISHING; REVIEW; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MICE; MICE, TRANSGENIC; PRESENILINS; RATS; TAU PROTEINS;

EID: 68049110420     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78-84.
2. Lemaire HG, Salbaum JM, Multhaup G, Kang J, Bayney RM, Unterbeck A, et al. The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons. Nucleic Acids Res 1989;17:517-522
3. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990;87:257-263 (Pubitemid 20146047)
4. Schubert D, Jin LW, Saitoh T, Cole G. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 1989;3:689-694
5. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990;248:1122-1124 (Pubitemid 20189868)
6. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-327
7. Anderson JP, Chen Y, Kim KS, Robakis NK. An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. J Neurochem 1992;59:2328-2331
8. Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem 2005;93:769-792
9. Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Díaz P, et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet 1992;2:340-342
10. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995;11:219-222
11. Bird TD, Sumi SM, Nemens EJ, Nochlin D, Schellenberg G, Lampe TH, et al. Phenotypic heterogeneity in familial Alzheimer's disease: a study of 24 kindreds. Ann Neurol 1989;25:12-25. (Pubitemid 19032838)
12. Zekanowski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D, Ilkowski J, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 2003;184:991-996 (Pubitemid 38182828)
13. Hmad-Annuar A, Tabrizi SJ, Fisher EM. Mouse models as a tool for understanding neurodegenerative diseases. Curr Opin Neurol 2003; 16:451-458 (Pubitemid 36951820)
14. Sarasa M. Experimental models for Alzheimer's disease research. Rev Neurol 2006;42:297-301. (Pubitemid 47378396)
15. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-150 (Pubitemid 30082357)
16. Carrodeguas JA, Rodolosse A, Garza MV, Sanz-Clemente A, Pérez-Pe R, Lacosta AM, et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience 2005; 134:1285-1300 (Pubitemid 41207377)
17. Langui D, Lachapelle F, Duyckaerts C. Animal models of neurodegenerative diseases. Med Sci (París) 2007;23:180-186
18. Langui D, Lachapelle F, Duyckaerts C. Animal models of neurodegenerative diseases. Med Sci (París) 2007;23:180-186
19. Sarasa M. Experimental models for Alzheimer's disease research. Rev Neurol 2006;42:297-301. (Pubitemid 47378396)
20. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115:5-38. (Pubitemid 50005258)
21. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem 2000;275:33729-33737
22. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, et al. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997;3:1021-1023
23. Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci USA 1999;96:742-747 (Pubitemid 29061279)
24. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807. (Pubitemid 46174498)
25. Jiménez-Escrig A. Transgenic animals in Neurology. En: Jiménez-Escrig A, editor. Texbook of neurogenetics. Madrid: Díaz de Santos, 2007; p. 39-49.
26. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-289
27. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11:213-228
28. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-527
29. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. Nature 1998; 395:755-756 (Pubitemid 28485431)
30. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 1999;113:982-990 (Pubitemid 30130872)
31. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998;43:380-383 (Pubitemid 28113601)
32. Rovelet-Lecrux A, Hannequin D, Raux G, Le MN, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-26 (Pubitemid 43011878)
33. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 1995;11:177-184
34. Sago H, Carlson EJ, Smith DJ, Kilbridge J, Rubin EM, Mobley WC, et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95:6256-6261 (Pubitemid 28248999)
35. Hunter CL, Isacson O, Nelson M, Bimonte-Nelson H, Seo H, Lin L, et al. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res 2003; 45:437-445 (Pubitemid 36355843)
36. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001;98:10439-10444 (Pubitemid 32803038)
37. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001;98:10439-10444 (Pubitemid 32803038)
38. Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm AC. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging 2004;25:873-884 (Pubitemid 38813167)
39. Shukkur EA, Shimohata A, Akagi T, Yu W, Yamaguchi M, Murayama M, et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum Mol Genet 2006;15:2752-2762 (Pubitemid 44400402)
40. O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005;309:2033-2037 (Pubitemid 41362316)
41. Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci 2003;23:6788-6792 (Pubitemid 36951206)
42. Borchelt DR, Ratovitski T, van LJ, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-945 (Pubitemid 27471397)
43. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100. (Pubitemid 28133087)
44. Hartmann J, Erb C, Ebert U, Baumann KH, Popp A, Konig G, eCentral cholinergic functions in human amyloid precursor protein knock-in/presenilin- 1 transgenic mice. Neuroscience 2004;125:1009-1017 (Pubitemid 38553907)
45. Willem M, Dewachter I, Smyth N, van DT, Borghgraef P, Haass C, et al. Beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol 2004;165:1621-1631 (Pubitemid 39435161)
46. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999;6:231-244 (Pubitemid 29470035)
47. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100. (Pubitemid 28133087)
48. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pérez-Tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-713
49. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pérez-Tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-713
50. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013 (Pubitemid 26424026)
51. Borchelt DR, Ratovitski T, van LJ, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-945 (Pubitemid 27471397)
52. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997;89:629-639 (Pubitemid 27511773)
53. Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 1977;116:207-225
54. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989;8:393-399 (Pubitemid 19274956)
55. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989;8:393-399 (Pubitemid 19274956)
56. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-1491 (Pubitemid 32801551)
57. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476-481 (Pubitemid 40994688)
58. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007;27:3650-3662 (Pubitemid 46557687)
59. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007;27:3650-3662 (Pubitemid 46557687)
60. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-421 (Pubitemid 36937044)
61. Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G, Pradier L, et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol Dis 2004;15:47-60. (Pubitemid 38134380)
62. Irizarry MC, Rebeck GW, Cheung B, Bales K, Paul SM, Holzman D, et al. Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann NY Acad Sci 2000;920:171-178 (Pubitemid 32056566)
63. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-289
64. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-527
65. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-527
66. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
67. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997;94:13287-13292 (Pubitemid 27518514)
68. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982 (Pubitemid 32101644)
69. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pérez-Tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-713
70. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100. (Pubitemid 28133087)
71. Borchelt DR, Ratovitski T, van LJ, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-945 (Pubitemid 27471397)
72. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000;20:4050-4058 (Pubitemid 30365675)
73. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005;25:9694-9703 (Pubitemid 41510910)
74. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement- inhibited Alzheimer's mice. Proc Natl Acad Sci USA 2002;99:10837-10842 (Pubitemid 34907063)
75. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004;7:954-960 (Pubitemid 39129504)
76. Cheng IH, Palop JJ, Espósito LA, Bien-Ly N, Yan F, Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004;10:1190-1192 (Pubitemid 39540434)
77. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005;47:191-199 (Pubitemid 41019251)
78. Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 2004;24:4657-4667 (Pubitemid 38656621)
79. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002;22:9340-9351 (Pubitemid 35356177)
80. Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O, Hashikawa T, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 2001;8:1036-1045 (Pubitemid 34017097)
81. Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K, et al. Tau filament formation and associative memory deficit in aged mice ex- pressing mutant (R406W) human tau. Proc Natl Acad Sci USA 2002; 99:13896-13901 (Pubitemid 35215477)
82. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005;25:10637-10647 (Pubitemid 41681911)
83. Andorfer C, Kress Y, Espinoza M, de SR, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003;86:582-590 (Pubitemid 36897439)
84. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-1491 (Pubitemid 32801551)
85. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-421 (Pubitemid 36937044)
86. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11:213-228
87. Dodart JC, Bales KR, Gannon KS, Greene SJ, Demattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457 (Pubitemid 34454251)
88. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807. (Pubitemid 46174498)
89. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-150 (Pubitemid 30082357)
90. Langui D, Lachapelle F, Duyckaerts C. Animal models of neurodegenerative diseases. Med Sci (París) 2007;23:180-186
91. Langui D, Lachapelle F, Duyckaerts C. Animal models of neurodegenerative diseases. Med Sci (París) 2007;23:180-186
92. Sarasa M. Experimental models for Alzheimer's disease research. Rev Neurol 2006;42:297-301. (Pubitemid 47378396)
93. Hmad-Annuar A, Tabrizi SJ, Fisher EM. Mouse models as a tool for understanding neurodegenerative diseases. Curr Opin Neurol 2003;16:451-458 (Pubitemid 36951820)
94. Wang J, Tanila H, Puolivali J, Kadish I, van GT. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 2003;14:318-327